ClinicalTrials.gg
CompletedNCT00147602SPARCLUpdated Apr 22, 2015

Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke

A Phase 4 interventional study of atorvastatin in Cardiovascular Disease, sponsored by Pfizer. Completed at 130 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-04-22.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
4,732
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To determine whether Lipitor reduces stroke, compared to placebo in patients who have had a previous stroke or transient ischemic attack.

02

Conditions studied

  • Cardiovascular Disease
03

In context

Cardiovascular Diseases

5,372 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's enrollment of 4,732 is above the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previous stroke or

Exclusion criteria

Exclusion Criteria:

  • coronary heart disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
4,732 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Time to occurrence of fatal or non-fatal stroke

Secondary outcomes

  1. Time to occurrence of an acute coronary event, consisting of cardiac death, nonfatal myocardial infarction, resuscitated cardiac arrest or unstable angina.

  2. Time to occurrence of a cerebrovascular event, defined as fatal or nonfatal stroke or TIA.

07

Study locations

130 sites
  • Pfizer Investigational Site
    East Gosford, New South Wales 2250, Australia
  • Pfizer Investigational Site
    Randwick, Sydney, New South Wales 2031, Australia
  • Pfizer Investigational Site
    Footscray, Victoria 3011, Australia
  • Pfizer Investigational Site
    Heidelberg Heights, Victoria 3081, Australia
  • Pfizer Investigational Site
    Parkville, Victoria 3050, Australia
  • Pfizer Investigational Site
    Prahran, Victoria 3181, Australia
  • Pfizer Investigational Site
    Perth, Western Australia 6000, Australia
  • Pfizer Investigational Site
    Graz, A-8036, Austria
  • Pfizer Investigational Site
    Innsbruck, A-6020, Austria
  • Pfizer Investigational Site
    Villach, A-9504, Austria
  • Pfizer Investigational Site
    Wien, 1160, Austria
  • Pfizer Investigational Site
    Gent, 9000, Belgium
  • Pfizer Investigational Site
    Leuven, 3000, Belgium
  • Pfizer Investigational Site
    Tielt, 8700, Belgium
  • Pfizer Investigational Site
    Waregem, 8790, Belgium
  • Pfizer Investigational Site
    Porto Alegre, RS 90610-000, Brazil
  • Pfizer Investigational Site
    Sao Paulo, SP 05403-000, Brazil
  • Pfizer Investigational Site
    Vina Del Mar, Chile
  • Pfizer Investigational Site
    Brno, 65691, Czech Republic
  • Pfizer Investigational Site
    Ostrava-Poruba, 70852, Czech Republic
  • Pfizer Investigational Site
    Ostrava, 70384, Czech Republic
  • Pfizer Investigational Site
    Pilsen, 30599, Czech Republic
  • Pfizer Investigational Site
    Prague 4, 14021, Czech Republic
  • Pfizer Investigational Site
    Zlin, 76275, Czech Republic
  • Pfizer Investigational Site
    Copenhagen Nv, 2400, Denmark
  • Pfizer Investigational Site
    Glostrup, 2600, Denmark
  • Pfizer Investigational Site
    Hellerup, 2900, Denmark
  • Pfizer Investigational Site
    Hus, Helsinki, 00029, Finland
  • Pfizer Investigational Site
    Kotka, 48210, Finland
  • Pfizer Investigational Site
    Kuopio, 70210, Finland
  • Pfizer Investigational Site
    Lahti, 15850, Finland
  • Pfizer Investigational Site
    Lappeenranta, 53130, Finland
  • Pfizer Investigational Site
    Oulu, 90220, Finland
  • Pfizer Investigational Site
    Saint Denis, Cedex 1 93205, France
  • Pfizer Investigational Site
    Paris, Cedex 20 75970, France
  • Pfizer Investigational Site
    Toulouse, Cedex 3 31059, France
  • Pfizer Investigational Site
    Bourg En Bresse, Cedex 01012, France
  • Pfizer Investigational Site
    Besancon, 25030, France
  • Pfizer Investigational Site
    Marseille, 13385, France
  • Pfizer Investigational Site
    Nice, 06000, France
  • Pfizer Investigational Site
    Paris, 75018, France
  • Pfizer Investigational Site
    Bad Rodach, 96476, Germany
  • Pfizer Investigational Site
    Berlin, 10117, Germany
  • Pfizer Investigational Site
    Essen, 45122, Germany
  • Pfizer Investigational Site
    Heidelberg, Germany
  • Pfizer Investigational Site
    Leipzig, 04103, Germany
  • Pfizer Investigational Site
    Mannheim, 69135, Germany
  • Pfizer Investigational Site
    Minden, 32427, Germany
  • Pfizer Investigational Site
    Muenchen, 81377, Germany
  • Pfizer Investigational Site
    Muenchen, 81545, Germany
  • Pfizer Investigational Site
    Muenchen, 81675, Germany
  • Pfizer Investigational Site
    Muenster, 48149, Germany
  • Pfizer Investigational Site
    Regensburg, 93053, Germany
  • Pfizer Investigational Site
    Athens, Melissia 15127, Greece
  • Pfizer Investigational Site
    Athens, 11527, Greece
  • Pfizer Investigational Site
    Athens, 15127, Greece
  • Pfizer Investigational Site
    Thessaloniki, 54636, Greece
  • Pfizer Investigational Site
    Thessaloniki, 57010, Greece
  • Pfizer Investigational Site
    Haifa, 34362, Israel
  • Pfizer Investigational Site
    Holon, 58100, Israel
  • Pfizer Investigational Site
    Petach-tikva, 49372, Israel
  • Pfizer Investigational Site
    Tel Aviv, Israel
  • Pfizer Investigational Site
    Via Brunamonti 15, Perugia 06122, Italy
  • Pfizer Investigational Site
    Bari, 70124, Italy
  • Pfizer Investigational Site
    Bergamo, 24128, Italy
  • Pfizer Investigational Site
    Genova, 16132, Italy
  • Pfizer Investigational Site
    Milano, 20132, Italy
  • Pfizer Investigational Site
    Monza, 20052, Italy
  • Pfizer Investigational Site
    Monterrey, Nuevo Leon 64460, Mexico
  • Pfizer Investigational Site
    Rotterdam, GD 3015, Netherlands
  • Pfizer Investigational Site
    Almelo, 7609 PP, Netherlands
  • Pfizer Investigational Site
    Delft, 2625 AD, Netherlands
  • Pfizer Investigational Site
    Goes, 4462 RA, Netherlands
  • Pfizer Investigational Site
    RB Groningen, 9700, Netherlands
  • Pfizer Investigational Site
    Tilburg, 5022 GC, Netherlands
  • Pfizer Investigational Site
    Takapuna, Auckland, New Zealand
  • Pfizer Investigational Site
    Auckland, New Zealand
  • Pfizer Investigational Site
    Christchurch, New Zealand
  • Pfizer Investigational Site
    Bialystok, 15-276, Poland
  • Pfizer Investigational Site
    Krakow, 31-503, Poland
  • Pfizer Investigational Site
    Lublin, 20-954, Poland
  • Pfizer Investigational Site
    Poznan, 30-355, Poland
  • Pfizer Investigational Site
    Sosnowiec, 41-200, Poland
  • Pfizer Investigational Site
    Warszawa, 01-211, Poland
  • Pfizer Investigational Site
    Warszawa, 02 - 957, Poland
  • Pfizer Investigational Site
    Wroclaw, 50-420, Poland
  • Pfizer Investigational Site
    Coimbra Codex, 3049, Portugal
  • Pfizer Investigational Site
    Lisboa, 1600, Portugal
  • Pfizer Investigational Site
    Porto, 4000, Portugal
  • Pfizer Investigational Site
    Bratislava, 81369, Slovakia
  • Pfizer Investigational Site
    Bratislava, 83301, Slovakia
  • Pfizer Investigational Site
    Bloemfontein, 9301, South Africa
  • Pfizer Investigational Site
    Cape Town, 7800, South Africa
  • Pfizer Investigational Site
    Parow, 7505, South Africa
  • Pfizer Investigational Site
    L'Hospitalet (BCN), Barcelona 08907, Spain
  • Pfizer Investigational Site
    Málaga, Malaga 29010, Spain
  • Pfizer Investigational Site
    Alicante, 03010, Spain
  • Pfizer Investigational Site
    Barcelona, 08035, Spain
  • Pfizer Investigational Site
    Barcelona, 08036, Spain
  • Pfizer Investigational Site
    Burgos, 09005, Spain

Showing the first 100 of 130 sites across 25 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006 Aug 10;355(6):549-59. doi: 10.1056/NEJMoa061894. Erratum In: N Engl J Med. 2018 Jun 13;378(25):2450. doi: 10.1056/NEJMx180019. PubMed 16899775 ↗
  • Szarek M, Amarenco P, Callahan A, DeMicco D, Fayyad R, Goldstein LB, Laskey R, Sillesen H, Welch KM; SPARCL Committees and Investigators. Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial. J Am Coll Cardiol. 2020 May 5;75(17):2110-2118. doi: 10.1016/j.jacc.2020.03.015. Epub 2020 Mar 16. PubMed 32194196 ↗
  • Vogt L, Bangalore S, Fayyad R, Melamed S, Hovingh GK, DeMicco DA, Waters DD. Atorvastatin Has a Dose-Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double-Blind Randomized Controlled Trials. J Am Heart Assoc. 2019 May 7;8(9):e010827. doi: 10.1161/JAHA.118.010827. PubMed 31020900 ↗
  • Ganz P, Amarenco P, Goldstein LB, Sillesen H, Bao W, Preston GM, Welch KMA; SPARCL Steering Committee. Association of Osteopontin, Neopterin, and Myeloperoxidase With Stroke Risk in Patients With Prior Stroke or Transient Ischemic Attacks: Results of an Analysis of 13 Biomarkers From the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial. Stroke. 2017 Dec;48(12):3223-3231. doi: 10.1161/STROKEAHA.117.017965. Epub 2017 Nov 7. PubMed 29114094 ↗
  • Byun YS, Yang X, Bao W, DeMicco D, Laskey R, Witztum JL, Tsimikas S; SPARCL Trial Investigators. Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack. J Am Coll Cardiol. 2017 Jan 17;69(2):147-158. doi: 10.1016/j.jacc.2016.10.057. PubMed 28081824 ↗
  • Amarenco P, Callahan A 3rd, Campese VM, Goldstein LB, Hennerici MG, Messig M, Sillesen H, Welch KM, Wilson DJ, Zivin JA. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial. Stroke. 2014 Oct;45(10):2974-82. doi: 10.1161/STROKEAHA.114.005832. Epub 2014 Aug 21. PubMed 25147328 ↗
  • Ovbiagele B, Goldstein LB, Amarenco P, Messig M, Sillesen H, Callahan A 3rd, Hennerici MG, Zivin J, Welch KM; SPARCL Investigators. Prediction of major vascular events after stroke: the stroke prevention by aggressive reduction in cholesterol levels trial. J Stroke Cerebrovasc Dis. 2014 Apr;23(4):778-84. doi: 10.1016/j.jstrokecerebrovasdis.2013.12.001. Epub 2014 Feb 24. PubMed 24582273 ↗
  • Callahan A, Amarenco P, Goldstein LB, Sillesen H, Messig M, Samsa GP, Altafullah I, Ledbetter LY, MacLeod MJ, Scott R, Hennerici M, Zivin JA, Welch KM; SPARCL Investigators. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Arch Neurol. 2011 Oct;68(10):1245-51. doi: 10.1001/archneurol.2011.146. Epub 2011 Jun 13. PubMed 21670382 ↗
  • Schwartz GG, Chaitman BR, Goldberger JJ, Messig M. High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Am Heart J. 2011 May;161(5):993-9. doi: 10.1016/j.ahj.2011.02.002. PubMed 21570534 ↗
  • Amarenco P, Goldstein LB, Sillesen H, Benavente O, Zweifler RM, Callahan A 3rd, Hennerici MG, Zivin JA, Welch KM; Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2010 Mar;41(3):426-30. doi: 10.1161/STROKEAHA.109.564781. Epub 2010 Jan 28. PubMed 20110538 ↗
  • Amarenco P, Goldstein LB, Callahan A 3rd, Sillesen H, Hennerici MG, O'Neill BJ, Rudolph AE, Simunovic L, Zivin JA, Welch KM; SPARCL Investigators. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis. 2009 Jun;204(2):515-20. doi: 10.1016/j.atherosclerosis.2008.09.008. Epub 2008 Sep 18. PubMed 18962621 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 1998 and a completion of Nov 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2005
First posted
Sep 7, 2005
Start
Nov 1998
Completion
Nov 2005
Last update
Apr 22, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Apr 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00147602
Lead sponsor
Pfizer
First posted
Sep 7, 2005
Start date
Nov 1998
Completion
Nov 2005
Last update
Apr 22, 2015

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion